Ibrutinib (PCI-32765)

For research use only. Not for use in humans.

目录号:S2680 中文名称:依鲁替尼

Ibrutinib (PCI-32765) Chemical Structure

CAS No. 936563-96-1

Ibrutinib (PCI-32765)是一种有效的,高选择性的Brutons tyrosine kinase (Btk)抑制剂,无细胞试验中IC50为0.5 nM,对Bmx, CSK, FGR, BRK及HCK适度有效,对EGFR, Yes, ErbB2, JAK3等作用效果较弱。Ibrutinib 可作为Btk配体用于合成包括P13I在内的一系列PROTAC

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 2226.41 现货
RMB 1392.54 现货
RMB 7922.62 现货
RMB 20229.3 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Ibrutinib (PCI-32765)发表文献411篇:

产品安全说明书

Target Protein Ligand抑制剂选择性比较

生物活性

产品描述 Ibrutinib (PCI-32765)是一种有效的,高选择性的Brutons tyrosine kinase (Btk)抑制剂,无细胞试验中IC50为0.5 nM,对Bmx, CSK, FGR, BRK及HCK适度有效,对EGFR, Yes, ErbB2, JAK3等作用效果较弱。Ibrutinib 可作为Btk配体用于合成包括P13I在内的一系列PROTAC
靶点
BTK [1]
(Cell-free assay)
BLK [1]
(Cell-free assay)
Bmx [1]
(Cell-free assay)
CSK [1]
(Cell-free assay)
FGR [1]
(Cell-free assay)
0.5 nM 0.5 nM 0.8 nM 2.3 nM 2.3 nM
体外研究

Ibrutinib有效可逆且选择性抑制Btk酶活性。Ibrutinib作用于 BCR 通路激活的 DOHH2细胞系, 抑制Btk自磷酸化, Btk's 生理底物 PLCγ磷酸化, 和更远一点的下游激酶ERK的磷酸化,IC50分别为11 nM, 29 nM 和 13 nM。[1] Ibrutinib作用于慢性淋巴细胞白血病 (CLL) 细胞,诱导细胞毒性,这种作用存在剂量和时间依赖性。此外, Ibrutinib诱导 caspase依赖性细胞死亡通路激活,且在TLR信号后,抑制CLL细胞增殖能力。[2] 最新研究显示Ibrutinib抑制 BCR激活的原代 B细胞增殖,IC50 为8 nM,且抑制 原代单核细胞中TNFα, IL-1β 和 IL-6产量, IC50 分别为2.6 nM, 0.5 nM, 和 3.9 nM。 [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human Rec1 cells NV;yUYFPTnWwY4Tpc44h[XO|YYm= M13aZ|IvPSEQvF2= M3LVbVYhcA>? M1nBPWlvcGmkaYTpc44hd2ZiTInuJJBpd3OyaH;yfYxifGmxbjDpckBpfW2jbjDS[YMyKGOnbHzzJIF1KDJwNTD1UUBqdmO3YnH0[YQh\m:{IE[gbJJ{KGK7IGfld5Rmem5iYnzveJRqdmdibXX0bI9l NUDWfmJDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyNlI5PzdpPkK1NlIzQDd5PD;hQi=>
human WSU-NHL cells MmXMR5l1d3SxeHnjxsBie3OjeR?= NWPueIh1PzJiaB?= MWDDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDXV3UuVkiOIHPlcIx{KGG|c3Xzd4VlKGG|IHfyc5d1cCCrbnjpZol1cW:wIHHmeIVzKDd{IHjyd{BjgSCFZXzsWIl1\XJvR3zvJIx2dWmwZYPj[Y51KGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTFwMEmg{txO NW\jdHM5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NVUzQTFpPkK0PVE2OjlzPD;hQi=>
human SU-DHL6 cells Ml7wR5l1d3SxeHnjxsBie3OjeR?= MX63NkBp M3Oz[2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHNWNUSKTE[gZ4VtdHNiYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiN{KgbJJ{KGK7IFPlcIxVcXSncj3HcI8hdHWvaX7ld4NmdnRiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD61PEDPxE1w MmLyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MUWyPVEoRjJ2OUG1NlkyRC:jPh?=
human DOHH2 cells NHTVcGREgXSxdH;4bYPDqGG|c3H5 MnvEO|IhcA>? MYrDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDEU2hJOiClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghcW6qaXLpeIlwdiCjZoTldkA4OiCqcoOgZpkhS2WubGTpeIVzNUeubzDseY1qdmW|Y3XueEBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjRzIN88UU4> NUnmXZJpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NVUzQTFpPkK0PVE2OjlzPD;hQi=>
Sf9 cells NEi0fVZHfW6ldHnvckBie3OjeR?= M4DvV|EhcA>? MYXJcohq[mm2aX;uJI9nKEy\Tj3BJIV5eHKnc4Pl[EBqdiCVZkmgZ4VtdHNiYX\0[ZIhPjBibXnud{BjgSCWUj3GVmVVKEG|c3H5MEBKSzVyPUCuNkDPxE1w NITJOGo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUm1PFU1Pyd-MkG5OVg2PDd:L3G+
human Ramos cells MlTiSpVv[3Srb36gZZN{[Xl? MXuxJIg> NWLDW5B{UW6qaXLpeIlwdiCxZjDCeIshcW5iaIXtZY4hWmGvb4OgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCSTFOt[4FudWF{IIDoc5NxcG:{eXzheIlwdiCjdDDUfZIyOjF5IHHmeIVzKDFiaIKgZpkhX2W|dHXyckBjdG:2IHHuZYx6e2m|LDDJR|UxRTF2IH7NMi=> M2Ox[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUG1NlkyLz5{NEmxOVI6OTxxYU6=
human Pfeiffer cells NFSzb3RHfW6ldHnvckBie3OjeR?= MmL1O|IhcA>? NULCNGRzS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hWG[naX\m[ZIh[2WubIOgZZN{\XO|ZXSgZZMh\3Kxd4ToJIlvcGmkaYTpc44h[W[2ZYKgO|IhcHK|IHL5JGNmdGyWaYTldk1IdG9ibIXtbY5me2OnboSgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NkBvVS5? MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlzNUK5NUc,OjR7MUWyPVE9N2F-
Sf9 cells M3PmVGZ2dmO2aX;uJIF{e2G7 MWmxJIg> MWHJcohq[mm2aX;uJI9nKGi3bXHuJIZ2dGxvbHXu[5RpKEKWSzDlfJBz\XO|ZXSgbY4hW2Z7IHPlcIx{KHW|aX7nJGZCVS2VcnP0bYRmKHCncITp[IUh[XNic4Xid5Rz[XSnIHHmeIVzKDZyIH3pcpMh[nliVGKtSnJGXCCDc4Phfg+9lCCLQ{WwQVAvPSCwTT6= MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl3OEW0O{c,OjF7NUi1OFc9N2F-
Sf9 insect cells MXPGeY5kfGmxbjDhd5NigQ>? NWXz[pFqPjBibXnudy=> M2KzWWlEPTBiPTCwMlAxODNizszN MnrpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjlzNE[xN|YoRjJ7MUS2NVM3RC:jPh?=
sf9 cells MnfESpVv[3Srb36gZZN{[Xl? NEniWIFKSzVyIE2gNE4xODB|IN88US=> MlT0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd7OUS3N|YoRjJ5OUm0O|M3RC:jPh?=
Sf9 insect cells NIC0TohHfW6ldHnvckBie3OjeR?= NY\6OXd3PjBibXnudy=> MorMTWM2OCB;IECuNFAxOzRizszN M3rOS|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OUGyNVc2Lz5{N{mxNlE4PTxxYU6=
Sf9 insect cells MnjMSpVv[3Srb36gZZN{[Xl? MWW2NEBucW6| MliwTWM2OCB;IECuNFAxOzRizszN MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR|Mkm0Okc,Ojh2M{K5OFY9N2F-
Sf9 insect cells NWTrNlA6TnWwY4Tpc44h[XO|YYm= NW\WU|Z2PjBibXnudy=> Mn7JTWM2OCB;IECuNFAxOzRizszN Mm\GQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd7NU[wN|coRjJ5OUW2NFM4RC:jPh?=
Sf9 cells MkjySpVv[3Srb36gZZN{[Xl? NXHtXJB6PjBibXnudy=> M{DrWWlEPTBiPTCwMlAxODRizszN NUj4T|RDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwNFYyPDNpPkOwNFA3OTR|PD;hQi=>
Sf9 cells MnzaSpVv[3Srb36gZZN{[Xl? NEfp[pk3OCCvaX7z M1Ky[2lEPTBiPTCwMlAxODVizszN MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl3OEW0O{c,OjF7NUi1OFc9N2F-
Ramos cells NUHoT|FvTnWwY4Tpc44h[XO|YYm= NULN[opXOSCq MWrJR|UxKD1iMD6wNFA2KM7:TR?= NEjyUFU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NFI3OSd-MkiyPFAzPjF:L3G+
Sf9 cells NHjxepVHfW6ldHnvckBie3OjeR?= MWW2NEBucW6| MWPJR|UxKD1iMD6wNFEh|ryP MnnUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByN{e2NFgoRjNyMEe3OlA5RC:jPh?=
Pfeiffer cells NWDrbZRGS3m2b4TvfIlkcXS7IHHzd4F6 MVq3NkBp NHjkSJFIUTVyIE2gNE4xODJizszN MmThQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MUWyPVEoRjJ2OUG1NlkyRC:jPh?=
B cells M3uwfWZ2dmO2aX;uJIF{e2G7 M3qyfVEhcA>? NYjieGU6UUN3MDC9JFAvODB2NjFOwG0> NH;2eHk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEK5NFk5QCd-M{CyPVA6QDh:L3G+
Sf9 insect cells MonqSpVv[3Srb36gZZN{[Xl? NEHmTIIzKHSxIE[wJI1qdnN? MoXMT4khRSByLkCwOFgh|ryP MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDNzNUW5O{c,Ojh|MUW1PVc9N2F-
Ramos cells MknuSpVv[3Srb36gZZN{[Xl? NEiwSHMyKGh? NYfFZ2RnUUN3MDC9JFAvODB5NTFOwG0> NFPBT2o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmxOVI6OSd-MkS5NVUzQTF:L3G+
Sf9 insect cells NFjYVlVHfW6ldHnvckBie3OjeR?= NFniNW03OCCvaX7z NI\IOHBKSzVyIE2gNE4xODhizszN MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDNzNUW5O{c,Ojh|MUW1PVc9N2F-
TMD8 cells M3jTXGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 NG[1UFc4OiCq NV62XmRyUUN3MDC9JFAvODFizszN NYn0XG5WRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm3NVUxOjNpPkK5O|E2ODJ|PD;hQi=>
CD19+ B cells M3vrSWZ2dmO2aX;uJIF{e2G7 MnfaNUBp MYjJR|UxKD1iMD6wNVIh|ryP MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR3N{m4Nkc,Ojl2NUe5PFI9N2F-
Sf9 insect cells NHHTNG9HfW6ldHnvckBie3OjeR?= NGizVoU3OCCvaX7z M3GxR2lEPTBiPTCwMlAyOiEQvF2= NETmUFQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEOxOVU6Pyd-MkizNVU2QTd:L3G+
Ramos cells Mo\2SpVv[3Srb36gZZN{[Xl? MYqxJIg> NWOyU5Q5UUN3MDC9JFAvODF2IN88US=> MnrmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MUWyPVEoRjJ2OUG1NlkyRC:jPh?=
Sf9 insect cells MorLSpVv[3Srb36gZZN{[Xl? M{PvXlEhcA>? NGHEbI5KSzVyIE2gNE4xOTR2IN88US=> MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTdzNUCyN{c,Ojl5MUWwNlM9N2F-
Sf9 insect cells NEC2c2VHfW6ldHnvckBie3OjeR?= M2HrW|YxKG2rboO= M1HlUmlEPTBiPTCwMlAyPjFizszN MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTF2NkGzOkc,OjlzNE[xN|Y9N2F-
HCC827 cells MlS0RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? NF\rXIE4OiCq NWHLdVlYUUN3MDC9JFAvODN7IN88US=> MnewQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh5M{S1PFEoRjJ6N{O0OVgyRC:jPh?=
PC9 cells M4LYc2Z2dmO2aX;uJIF{e2G7 MXm3NkBp NUHxOFVqT0l3MDC9JFAvODVizszN MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
Sf9 cells MX3GeY5kfGmxbjDhd5NigQ>? MmjTOlAhdWmwcx?= MojSTWM2OCB;IECuNUDPxE1? MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODByNkG0N{c,OzByME[xOFM9N2F-
H3255 cells MYPGeY5kfGmxbjDhd5NigQ>? MVK3NkBp MXPHTVUxKD1iMD6xNUDPxE1? MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
BaF3 cells MWHGeY5kfGmxbjDhd5NigQ>? NH\ueWE4OiCq M{W2TWdKPTBiPTCwMlEzKM7:TR?= MnfxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ4M{C1OVMoRjJ4NkOwOVU{RC:jPh?=
BAF3 cells M{HWVmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 NFPG[2Q4OiCq NWLHO2xZT0l3MDC9JFAvOTJizszN M1LEfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OUW2PVI{Lz5{OEm1OlkzOzxxYU6=
Sf9 insect cells NFLQSnZHfW6ldHnvckBie3OjeR?= MnzmOlAhdWmwcx?= M{D6U2lEPTBiPTCwMlEzOyEQvF2= MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDNzNUW5O{c,Ojh|MUW1PVc9N2F-
Sf9 insect cells MX3GeY5kfGmxbjDhd5NigQ>? NYThW5ltPjBibXnudy=> MnKwTWM2OCB;IECuNVQ3KM7:TR?= NFnQe2Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEOxOVU6Pyd-MkizNVU2QTd:L3G+
BAF3 cells MYXGeY5kfGmxbjDhd5NigQ>? M2GxO|czKGh? MWTHTVUxKD1iMD6xOkDPxE1? NH7QRVE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NlEzOid-MkiyPFIyOjJ:L3G+
Sf9 cells NVPiXnRtTnWwY4Tpc44h[XO|YYm= NVTIeZEyPjBibXnudy=> NXTvOmNuUUN3MDC9JFAvOiEQvF2= MnixQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF7NUi1OFcoRjJzOUW4OVQ4RC:jPh?=
MV411 cells MUDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MlHpS2k2OCB;IECuNlUh|ryP NWTZTZlERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkizNVU2QTdpPkK4N|E2PTl5PD;hQi=>
MV4-11 cells MYjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>? MUS3NkBp NIG3Z3lIUTVyIE2gNE4{OyEQvF2= NF7nSmw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nk[zNFU2Oyd-Mk[2N|A2PTN:L3G+
MV4-11 cells MV7BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>? M4nCVlczKGh? MlvCS2k2OCB;IECuN|Mh|ryP M4m1OlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OUW2PVI{Lz5{OEm1OlkzOzxxYU6=
DOHH2 cells NVrDbVRZS3m2b4TvfIlkcXS7IHHzd4F6 Mn7RO|IhcA>? M4X6[GdKPTBiPTCwMlQyKM7:TR?= NYrtcJVFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NVUzQTFpPkK0PVE2OjlzPD;hQi=>
HCC827 cells M3m2RWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 NW\lV5hWQTZiaB?= NGPXTWhGSzVyIE2gNE41PSEQvF2= MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDh3M{W3OUc,Ojh6NUO1O|U9N2F-
SU-DHL6 cells MXPDfZRwfG:6aXPpeJkh[XO|YYm= NF;3Rpc4OiCq NYO0WVNGT0l3MDC9JFAvPThizszN M2TxTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUG1NlkyLz5{NEmxOVI6OTxxYU6=
M07e cells NFHIWYVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NUPiS5dGT0l3MDC9JFAvPTlizszN MmW1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh|MUW1PVcoRjJ6M{G1OVk4RC:jPh?=
NCI-H1975 cells NIq5eJVCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= MXy5OkBp MWXFR|UxKD1iMD62OEDPxE1? NV;xfoZtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki4OVM2PzVpPkK4PFU{PTd3PD;hQi=>
SU-DHL-2 cells MYXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M3mySmdKPTBiPTCwMlY1KM7:TR?= M3PCbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6M{G1OVk4Lz5{OEOxOVU6PzxxYU6=
HEK293T cells MWjGeY5kfGmxbjDhd5NigQ>? MX:xJIg> NH7wPFVKSzVyIE2gNE46KM7:TR?= NVO1SYo5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFAzPjFpPkK4NlgxOjZzPD;hQi=>
Ramos cells NWnaOYJ1SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= M4nuU|czKGh? NVfiXFRZUUN3MDC9JFAvQTJizszN NWmycmQ5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm3NVUxOjNpPkK5O|E2ODJ|PD;hQi=>
BA/F3 cells NFS5d2VCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= MoHxO|IhcA>? NFT2fJhKSzVyIE2gNUDPxE1? NX;oTXg6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[yOVg2OjFpPkK2NlU5PTJzPD;hQi=>
WSU-NHL cells NUezPHRnS3m2b4TvfIlkcXS7IHHzd4F6 M4W0PFczKGh? NXzZeYZnT0l3MDC9JFEvODlizszN Mn61QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MUWyPVEoRjJ2OUG1NlkyRC:jPh?=
NCI-H1975 cells M3fsPGZ2dmO2aX;uJIF{e2G7 M1j5Z|czKGh? NVj6N4d1T0l3MDC9JFEvOiEQvF2= M4jifFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
NCI-H1975 cells NYrKbVBDSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= NIfGNZI4OiCq MUfJR|UxKD1iMT6yO{DPxE1? M{TrcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6N{O0OVgyLz5{OEezOFU5OTxxYU6=
Raji cells M4TocmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 MXK0PEBp NXWxR3hzUUN3MDC9JFEvPDlizszN NVLrO4JwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm1OlczQTVpPkK5OVY4Ojl3PD;hQi=>
Pfeiffer cells M3:5PWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NULwO2JVT0l3MDC9JFEvPiEQvF2= NEO1XGQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEOxOVU6Pyd-MkizNVU2QTd:L3G+
A431 cells MkSxRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? MmjEPVYhcA>? MXTFR|UxKD1iMj6zPEDPxE1? NWH6SZZKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki4OVM2PzVpPkK4PFU{PTd3PD;hQi=>
BAF3 cells NVm5VJFpSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= M1nN[|czKGh? MYnHTVUxKD1iMj61JO69VQ>? M{n1clxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OUW2PVI{Lz5{OEm1OlkzOzxxYU6=
U937 cells M1\LS2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MYnHTVUxKD1iMj65JO69VQ>? NYfPeIQyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkizNVU2QTdpPkK4N|E2PTl5PD;hQi=>
NB4 cells NImzfpNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NXnKT2JLT0l3MDC9JFMh|ryP M3HOe|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6M{G1OVk4Lz5{OEOxOVU6PzxxYU6=
Ramos cells M1zp[2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NWDuT2JQT0l3MDC9JFMvPCEQvF2= NXPuTHdtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkizNVU2QTdpPkK4N|E2PTl5PD;hQi=>
SKM1 cells NEHMfZNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MX;HTVUxKD1iMz62JO69VQ>? NGnNWHg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEOxOVU6Pyd-MkizNVU2QTd:L3G+
U2932 cells Ml;SS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MXTHTVUxKD1iND60JO69VQ>? NGjMcHM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEOxOVU6Pyd-MkizNVU2QTd:L3G+
Ramos cells NFf0fXZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= NW\5coJMPzJiaB?= NY[zNG9{UUN3MDC9JFUvOTRizszN NG\JT5o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MECwOlE1Oyd-M{CwNFYyPDN:L3G+
Ramos cells NEHNbmdCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= NF;pfGM1QCCq NUH1dGdWUUN3MDC9JFUvOTRizszN NWryVlB6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke5OVYxOzdpPkK3PVU3ODN5PD;hQi=>
Ramos cells NYHQPVZuSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= MVm0PEBp MUnJR|UxKD1iNT64PEDPxE1? MmDWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2M{K5OFYoRjJ6NEOyPVQ3RC:jPh?=
Ramos cells M1jPUGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 MWG3NkBp MWnJR|UxKD1iNj62NkDPxE1? NF62foE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUG0OlE{Pid-MkmxOFYyOzZ:L3G+
K562 cells NVPUblZ[SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= NFvXd3g1QCCq M1XYWGlEPTBiPTC3MlUh|ryP NHzHN3Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEC3O|YxQCd-M{CwO|c3ODh:L3G+
HL60 cells MVTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>? MmXSOFghcA>? Mlj4TWM2OCB;IEig{txO NFTOUZg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEC3O|YxQCd-M{CwO|c3ODh:L3G+
Ramos cells NYHJNJJ5SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= MnTFOFghcA>? NWXKbJY1UUN3MDC9JFgvOTFizszN MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzl7NEezOkc,Ojd7OUS3N|Y9N2F-
Ramos cells NUD1[XZLSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= Ml;POFghcA>? NHr6b2pKSzVyIE2gPE4zPiEQvF2= NXfpcHJWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm1OlczQTVpPkK5OVY4Ojl3PD;hQi=>
OCI-AML3 cells NXvIXooxT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M3;0TWdKPTBiPTC5MlIh|ryP NWXxTHZFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkizNVU2QTdpPkK4N|E2PTl5PD;hQi=>
BAF3 cells NYTuUHR2S3m2b4TvfIlkcXS7IHHzd4F6 Mn64O|IhcA>? MkjPS2k2OCB;IEGwJO69VQ>? MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjZ|MEW1N{c,OjZ4M{C1OVM9N2F-
BAF3 cells M4e2TWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 MVm3NkBp MXzHTVUxKD1iMUCg{txO MlXhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh7NU[5NlMoRjJ6OUW2PVI{RC:jPh?=
BAF3 cells NYK2VVNRT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M3X0VlczKGh? NFmzdoFIUTVyIE2gNVAh|ryP MlnwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEKxNlIoRjJ6MkiyNVIzRC:jPh?=
NAMALWA cells NH\QXXBCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= NFnY[mE4OiCq MkXKTWM2OCB;IEGwMlQ2KM7:TR?= NVzJc4ZwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmxOFYyOzZpPkK5NVQ3OTN4PD;hQi=>
Ramos cells M2PM[2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 MmLYOFghcA>? NGT5fm5KSzVyIE2gNVIvPiEQvF2= NVzYT5diRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke5NVIyPzVpPkK3PVEzOTd3PD;hQi=>
Raji cells M1rHU2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 NVH6NI9PPDhiaB?= NIfIOVZKSzVyIE2gNVQvOiEQvF2= MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODB5N{[wPEc,OzByN{e2NFg9N2F-
Raji cells MUTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>? NGHCboc1QCCq MUTJR|UxKD1iMUWuNkDPxE1? NULNVmhkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke5PVQ4OzZpPkK3PVk1PzN4PD;hQi=>
MIAPaCa2 cells NF;mUnZEgXSxdH;4bYNqfHliYYPzZZk> NEPWOZg{KGSjeYO= MlrUTWM2OCB;IEG2MlYh|ryP MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzB5N{KyPEc,OjdyN{eyNlg9N2F-
HeLa cells MUDDfZRwfG:6aXPpeJkh[XO|YYm= NGDZTYw{KGSjeYO= Mkn0TWM2OCB;IEG2Mlgh|ryP NYTQS2drRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkewO|czOjhpPkK3NFc4OjJ6PD;hQi=>
Raji cells NFW3eHNCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= MmXwOFghcA>? MnjyTWM2OCB;IEG5MlMh|ryP MmHOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd7MUKxO|UoRjJ5OUGyNVc2RC:jPh?=
Raji cells NHXy[VNCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= NF3LU2I1QCCq NV7XOopMUUN3MDC9JFE6NjNizszN NVvzV4k5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0N|I6PDZpPkK4OFMzQTR4PD;hQi=>
Raji cells NGXlPGVCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= MYC3NkBp NHHW[WhKSzVyIE2gNVkvPSEQvF2= NES5XIg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MECwOlE1Oyd-M{CwNFYyPDN:L3G+
Raji cells NHfaVm5CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= MmixOFghcA>? M1rLTmlEPTBiPTCxPU42KM7:TR?= M{\FNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OUW2NFM4Lz5{N{m1OlA{PzxxYU6=
NAMALWA cells MVfBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>? NV\VRXdWPzJiaB?= M1rId2lEPTBiPTCxPU43KM7:TR?= MljCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByME[xOFMoRjNyMEC2NVQ{RC:jPh?=
A2780 cells MVPDfZRwfG:6aXPpeJkh[XO|YYm= M2TyPFMh\GG7cx?= M3vzSGVEPTBiPTCyNE4yKM7:TR?= M3\VWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MEe3NlI5Lz5{N{C3O|IzQDxxYU6=
Raji cells MkXFRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? MnvNO|IhcA>? NEP4V2RKSzVyIE2gNlAvQDhizszN NWLvOYNmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmxOFYyOzZpPkK5NVQ3OTN4PD;hQi=>
A549 cells NX24PG9ESW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= MXW3NkBp NHfBO4tKSzVyIE2gNlEvPzlizszN NV72cmxRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki3N|Q2QDFpPkK4O|M1PThzPD;hQi=>
SW480 cells NGPTV5pEgXSxdH;4bYNqfHliYYPzZZk> M{XjU|Mh\GG7cx?= MUDJR|UxKD1iMkWuOkDPxE1? NVGwWIZXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkewO|czOjhpPkK3NFc4OjJ6PD;hQi=>
Ramos cells NVvsS3E5S3m2b4TvfIlkcXS7IHHzd4F6 MkXZNlQhcA>? MY\JR|UxKD1iMkiuO{DPxE1? MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ5NE[3OUc,Ojh{N{S2O|U9N2F-

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
pEGFR(Tyr1068) / EGFR; 

PubMed: 28061447     


Ibrutinib inhibitory effects on EGFRY1068 auto-phosphorylation in the HCC827 cell line at different time points by removal of drug after 4 h pretreatment.

pBTK / pPLCγ2 / pAKT / pERK / pJNK; 

PubMed: 23940282     


Mino (left panel) or Jeko1 (right panel) cells pretreated with vehicle or ibrutinib 10, 100, or 1000 nM were either stimulated with anti-IgM, CXCL12, or CXCL13 or treated with medium (Med) for 15 minutes and then immunoblotted for pBTK, pPLCγ2, pAKT, pERK, and pJNK.

28061447 23940282
Immunofluorescence
CD11b; 

PubMed: 30231870     


BV2 microglial cells were pretreated with ibrutinib (1 μM) or vehicle (1% DMSO) for 30 min, followed by treatment with LPS (1 μg/ml) or PBS for 5.5 h and immunostaining with an anti-CD11b antibody. Scale bar = 20 μm.

COX-2; 

PubMed: 30231870     


BV2 microglial cells were treated with vehicle (1% DMSO) or ibrutinib (1 μM) for 30 min, followed by PBS or LPS (1 μg/ml) for 5.5 h, and immunocytochemistry was conducted with anti-CD11b and anti-COX-2 antibodies. 

30231870
ELISA
hTNFα; 

PubMed: 26627823     


PBMs were isolated and pretreated with 1, 5, or 10 μm ibrutinib (IB) or left untreated (UT, −). Pretreated PBMs were incubated for 24 h in 96-well plates precoated without (PBS) or with 10 μg/ml whole human IgG. Cleared supernatants were collected and analyzed by ELISA for TNFα (n = 3).

IL-10; 

PubMed: 27792904     


LMP2A-negative (vector.1/.2) and -positive (express LMP2A) B cell lines were incubated in the absence or presence of increasing concentrations of Ibrutinib for 24 hours and supernatants were isolated for analysis using an IL-10 ELISA.

26627823 27792904
体内研究

Ibrutinib 作用于胶原诱导的关节炎模型,通过抑制B细胞活性,显著降低足肿胀和关节发炎等临床关节炎症状。Ibrutinib 作用于 MRL-Fas(lpr) 狼疮模型 ,降低肾疾病和自身抗体产量。[1] Ibrutinib 每天按25 mg/kg剂量作用于过继转移TCL1 的CLL小鼠模型, 产生短暂的早期淋巴细胞增多症,且延迟CLL 疾病进展。[4]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:

[1]

- 合并

激酶实验:

激酶, 33P-ATP, Ibrutinib, 和底物 [0.2 mg/mL 聚(EY)(4:1)]温育1小时后,使用33P 过滤结合实验测量体外激酶IC50值。
细胞实验:

[2]

- 合并
  • Cell lines: 慢性淋巴细胞白血病 (CLL) 细胞
  • Concentrations: 0.01 μM到100 μM
  • Incubation Time: 48小时
  • Method:

    进行MTT实验测定细胞毒性。细胞(CLL B 细胞或健康志愿者T 细胞或 NK细胞) 和不同浓度 Ibrutinib温育48小时。加入MTT试剂,实验板再温育20小时,然后使用溶于PBS的硫酸鱼精蛋白冲洗。加入DMSO,通过分光光度法使用Labsystems 酶标仪,在540 nm处测定吸光值。使用膜联蛋白/PI 流式细胞仪在不同时间点测量细胞活力。使用 Expo-ADC32 软件包分析数据。结果表示为总阳性细胞与对照组之比的百分数。加入100μM Z-VAD检测caspase依赖性凋亡。


    (Only for Reference)
动物实验:

[1]

- 合并
  • Animal Models: MRL-Fas(lpr) 狼疮模型和胶原诱导的关节炎模型
  • Dosages: ≤50 mg/kg
  • Administration: 口服处理
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 88 mg/mL (199.77 mM)
Ethanol 45 mg/mL (102.15 mM)
Water Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
5% DMSO+30% PEG 300+5% Tween 80+ddH2O
10mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 440.5
化学式

C25H24N6O2

CAS号 936563-96-1
储存条件 粉状
溶于溶剂
别名 N/A

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04294641 Recruiting Drug: Ibrutinib Chronic GVHD National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) January 5 2021 Phase 2
NCT04665115 Not yet recruiting Drug: Ibrutinib|Other: Quality-of-Life Assessment Asymptomatic COVID-19 Infection Laboratory-Confirmed|B-Cell Neoplasm|Chronic Lymphocytic Leukemia|Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma|Mantle Cell Lymphoma|Marginal Zone Lymphoma|Small Lymphocytic Lymphoma|Symptomatic COVID-19 Infection Laboratory-Confirmed|Waldenstrom Macroglobulinemia Academic and Community Cancer Research United|National Cancer Institute (NCI) December 31 2020 Phase 2
NCT04514393 Not yet recruiting Drug: Methotrexate|Drug: Ibrutinib|Drug: Temozolomide Primary Central Nervous System Lymphoma|PCNSL|Non Hodgkin Lymphoma Huiqiang Huang|Guangdong 999 Brain Hospital|Nanfang Hospital of Southern Medical University|Xian-Janssen Pharmaceutical Ltd.|Sun Yat-sen University December 1 2020 Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    How to reconstitute the compound S2680 for in vivo studies?

  • 回答:

    For in vivo study, we suggest to use 5% DMSO+30% PEG 300+5% Tween 80+ddH2O up to 10mg/ml.

Tags: 购买Ibrutinib (PCI-32765) | Ibrutinib (PCI-32765)供应商 | 采购Ibrutinib (PCI-32765) | Ibrutinib (PCI-32765)价格 | Ibrutinib (PCI-32765)生产 | 订购Ibrutinib (PCI-32765) | Ibrutinib (PCI-32765)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID